HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

B. Altunay, A. Morgenroth, M. Beheshti, A. Vogg, N.C.L. Wong, H.H. Ting, H.J. Biersack, E. Stickeler, F.M. Mottaghy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Citations (Web of Science)

Abstract

Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Results Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor. Conclusion While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.
Original languageEnglish
Pages (from-to)1371-1389
Number of pages19
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume48
Issue number5
Early online date12 Nov 2020
DOIs
Publication statusPublished - May 2021

Keywords

  • affibody
  • anti-her2 nanobody
  • antibody drug conjugate
  • emitting radiotherapeutic agent
  • her2
  • her2 receptor expression
  • immunotherapy
  • in-vivo
  • monoclonal-antibody
  • n-succinimidyl
  • nanobody
  • preclinical evaluation
  • residualizing label
  • single domain antibody
  • single-domain antibody
  • trastuzumab emtansine t-dm1
  • EMITTING RADIOTHERAPEUTIC AGENT
  • Affibody
  • MONOCLONAL-ANTIBODY
  • N-SUCCINIMIDYL
  • Antibody drug conjugate
  • Immunotherapy
  • TRASTUZUMAB EMTANSINE T-DM1
  • Nanobody
  • RESIDUALIZING LABEL
  • HER2 RECEPTOR EXPRESSION
  • SINGLE-DOMAIN ANTIBODY
  • Single domain antibody
  • ANTI-HER2 NANOBODY
  • IN-VIVO
  • HER2
  • PRECLINICAL EVALUATION

Cite this